HRP20110012T1 - Farmaceutski pripravak - Google Patents

Farmaceutski pripravak Download PDF

Info

Publication number
HRP20110012T1
HRP20110012T1 HR20110012T HRP20110012T HRP20110012T1 HR P20110012 T1 HRP20110012 T1 HR P20110012T1 HR 20110012 T HR20110012 T HR 20110012T HR P20110012 T HRP20110012 T HR P20110012T HR P20110012 T1 HRP20110012 T1 HR P20110012T1
Authority
HR
Croatia
Prior art keywords
tablet
layer according
serum concentrations
spray
sorbitol
Prior art date
Application number
HR20110012T
Other languages
English (en)
Croatian (hr)
Inventor
Thomas Ruediger
Maerz Frieder
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38179677&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20110012(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of HRP20110012T1 publication Critical patent/HRP20110012T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HR20110012T 2007-03-14 2008-03-13 Farmaceutski pripravak HRP20110012T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07104157A EP1970053A1 (en) 2007-03-14 2007-03-14 Pharmaceutical composition
PCT/EP2008/053009 WO2008110599A1 (en) 2007-03-14 2008-03-13 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
HRP20110012T1 true HRP20110012T1 (hr) 2011-02-28

Family

ID=38179677

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110012T HRP20110012T1 (hr) 2007-03-14 2008-03-13 Farmaceutski pripravak

Country Status (35)

Country Link
US (1) US20100143465A1 (da)
EP (2) EP1970053A1 (da)
JP (1) JP5742045B2 (da)
KR (1) KR101503674B1 (da)
CN (1) CN101641084B (da)
AR (1) AR065726A1 (da)
AT (1) ATE493119T1 (da)
AU (1) AU2008225754B2 (da)
BR (1) BRPI0808797A2 (da)
CA (1) CA2680608C (da)
CL (1) CL2008000733A1 (da)
CO (1) CO6220927A2 (da)
CY (1) CY1111350T1 (da)
DE (1) DE602008004217D1 (da)
DK (1) DK2120884T3 (da)
EA (1) EA018574B1 (da)
EC (1) ECSP099629A (da)
ES (1) ES2358770T3 (da)
HR (1) HRP20110012T1 (da)
IL (1) IL200125A (da)
MA (1) MA31251B1 (da)
MX (1) MX2009009201A (da)
MY (1) MY145089A (da)
NZ (1) NZ580185A (da)
PE (1) PE20090165A1 (da)
PL (1) PL2120884T3 (da)
PT (1) PT2120884E (da)
RS (1) RS51584B (da)
SI (1) SI2120884T1 (da)
TN (1) TN2009000371A1 (da)
TW (1) TWI406678B (da)
UA (1) UA96982C2 (da)
UY (1) UY30961A1 (da)
WO (1) WO2008110599A1 (da)
ZA (1) ZA200905224B (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
EP2203158A4 (en) * 2007-10-30 2012-12-26 Reddys Lab Ltd Dr PHARMACEUTICAL FORMULATIONS WITH TELMISARTAN AND HYDROCHLORTHIAZIDE
EP2291177A2 (en) 2008-05-05 2011-03-09 Farmaprojects, S.A. Stable pharmaceutical compositions and their processes for preparation suitable for industrial scale
CZ2008469A3 (cs) * 2008-07-31 2009-10-29 Zentiva, A. S. Telmisartan tablety
GB0822171D0 (en) * 2008-12-04 2009-01-14 Arrow Int Ltd Temisartan formulations
BRPI1013037A2 (pt) 2009-05-20 2019-09-24 Boehringer Ingelheim Ipharmaceuticals Inc "solução farmacêutica oral de telmisartan"
EP2844067A4 (en) * 2012-03-19 2015-11-25 Althera Life Sciences Llc ORAL TABLET FORMULATION OF ROSUV ASTATIN WITH IMMEDIATE RELEASE AND METOMETINE WITH DELAYED RELEASE
JP6344678B2 (ja) * 2013-09-27 2018-06-20 キョーリンリメディオ株式会社 テルミサルタン含有製剤及びその製造方法
JP6096328B2 (ja) * 2014-02-10 2017-03-15 富士フイルム株式会社 口腔内崩壊錠
BE1021954B1 (nl) * 2014-06-05 2016-01-28 Syral Belgium Nv Samenstelling van sorbitol met lage friabiliteit
FR3023128B1 (fr) 2014-07-01 2017-11-10 Roquette Freres Nouvelle composition edulcorante
JP5871294B1 (ja) * 2015-02-27 2016-03-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 即時放出経口錠剤
KR20170001921A (ko) 2015-06-26 2017-01-05 대원제약주식회사 안정성이 개선된 텔미사르탄을 함유하는 약제학적 조성물 및 이의 제조방법
CN106420739A (zh) * 2016-10-31 2017-02-22 扬子江药业集团四川海蓉药业有限公司 一种替米沙坦氨氯地平双层片及其制备方法
CN106800537B (zh) * 2017-01-18 2019-02-01 广东隆赋药业股份有限公司 丁苯酞-替米沙坦杂合物及其制备方法和用途
CN109316451B (zh) * 2017-07-31 2022-07-01 武汉朗来科技发展有限公司 治疗高血压和相关疾病的口服固体制剂
WO2019211159A1 (en) 2018-05-02 2019-11-07 Ferring B.V. Improved pharmaceutical formulations
MX2022000426A (es) 2019-07-09 2022-04-25 Boehringer Ingelheim Vetmedica Gmbh Telmisartan para el tratamiento de la hipertension en perros.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3245170A1 (de) * 1982-12-07 1984-06-07 Merck Patent Gmbh, 6100 Darmstadt Verbesserter sorbit, verfahren zur herstellung und verwendung
WO2000027397A1 (en) * 1998-11-06 2000-05-18 Glaxo Group Limited Antihypertensive medicaments containing lacidipine and telmisartan
FR2787110B1 (fr) * 1998-12-11 2001-02-16 Roquette Freres Sorbitol pulverulent et son procede de preparation
CN101352421A (zh) * 2002-01-16 2009-01-28 贝林格尔英格海姆法玛两合公司 一种制备基本上非结晶形式的替米沙坦的方法
DE10244681A1 (de) * 2002-09-24 2004-04-08 Boehringer Ingelheim International Gmbh Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung
DE102004008804A1 (de) * 2004-02-20 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mehrschichttablette
US20060078615A1 (en) * 2004-10-12 2006-04-13 Boehringer Ingelheim International Gmbh Bilayer tablet of telmisartan and simvastatin
CN103083318A (zh) * 2004-11-05 2013-05-08 贝林格尔.英格海姆国际有限公司 包含替米沙坦和氨氯地平的双层片剂
WO2006063737A1 (en) * 2004-12-17 2006-06-22 Boehringer Ingelheim International Gmbh Combination therapy comprising telmisartan and hydrochlorothiazide
US20060159747A1 (en) * 2004-12-17 2006-07-20 Boehringer Ingelheim International Gmbh Telmisartan and hydrochlorothiazide combination therapy

Also Published As

Publication number Publication date
TN2009000371A1 (fr) 2010-12-31
CO6220927A2 (es) 2010-11-19
UA96982C2 (ru) 2011-12-26
EA200901169A1 (ru) 2010-04-30
WO2008110599A1 (en) 2008-09-18
IL200125A0 (en) 2010-04-15
EP2120884B1 (en) 2010-12-29
PE20090165A1 (es) 2009-03-31
DK2120884T3 (da) 2011-02-07
HK1140692A1 (en) 2010-10-22
IL200125A (en) 2012-01-31
AU2008225754B2 (en) 2013-04-04
CL2008000733A1 (es) 2008-07-04
PT2120884E (pt) 2011-02-10
CY1111350T1 (el) 2015-08-05
BRPI0808797A2 (pt) 2013-01-15
MY145089A (en) 2011-12-30
US20100143465A1 (en) 2010-06-10
AU2008225754A1 (en) 2008-09-18
EP2120884A1 (en) 2009-11-25
UY30961A1 (es) 2008-10-31
ECSP099629A (es) 2009-10-30
MA31251B1 (fr) 2010-03-01
RS51584B (sr) 2011-08-31
CA2680608A1 (en) 2008-09-18
EP1970053A1 (en) 2008-09-17
EA018574B1 (ru) 2013-09-30
ZA200905224B (en) 2010-04-28
TWI406678B (zh) 2013-09-01
ES2358770T3 (es) 2011-05-13
JP5742045B2 (ja) 2015-07-01
KR20090119998A (ko) 2009-11-23
TW200900095A (en) 2009-01-01
DE602008004217D1 (de) 2011-02-10
JP2010530844A (ja) 2010-09-16
NZ580185A (en) 2011-11-25
MX2009009201A (es) 2009-09-08
AR065726A1 (es) 2009-06-24
CN101641084B (zh) 2013-04-10
CA2680608C (en) 2015-06-16
ATE493119T1 (de) 2011-01-15
PL2120884T3 (pl) 2011-05-31
CN101641084A (zh) 2010-02-03
SI2120884T1 (sl) 2011-04-29
KR101503674B1 (ko) 2015-03-18

Similar Documents

Publication Publication Date Title
HRP20110012T1 (hr) Farmaceutski pripravak
HRP20140212T1 (hr) Dvoslojna tableta koja sadrži telmisartan i amlodipin
US11167014B2 (en) Solid glp-1 derivative compositions for oral administration
NO20091501L (no) Farmasoytiske sammensetninger
RU2641198C3 (ru) Композиции glp-1 пептидов и их получение
EP3326620A1 (en) Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2- hydroxybenzoyl)amino)caprylic acid
AR071375A1 (es) Formulaciones para ingredientes farmaceuticos activos de permeabilidad deficiente, proceso de preparacion y producto
EP3250191A1 (en) Tablets comprising glp-1 agonist and enteric coating
PE20060174A1 (es) Nuevos compuestos alquinicos con actividad antagonista de mch y medicamentos que contienen estos compuestos
EA201001312A1 (ru) Твердая фармацевтическая композиция, содержащая непептидный антагонист рецептора ангиотензина ii и диуретик
JP2015522652A5 (da)
AR066924A1 (es) Formulacion de nevirapina de liberacion prolongada
CN107530287A (zh) 药物制剂
TR201906158T4 (tr) Etken Maddeler ile Farmasötik-Teknolojik Yardımcı Maddeler Arasındaki Etkileşimleri Engellemek Amacıyla Kullanılan Farmasötik Preparatlar İçin Ayırıcı Katmanlar.
AR075988A1 (es) Compuesto de piridiloxi - pirrolidina inhibidor de recaptacion de serotonina y norepinefrina, composicion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de dolor cronico
DE602005021475D1 (de) Magenresistente pharmazeutische dosierform mit n-(2-(2-phthalimidoethoxy)-acetyl)-l-alanyl-d-glutaminsäure (lk-423)
Hashem et al. Formulation and in vitro and in vivo evaluation of lipid-based terbutaline sulphate bi-layer tablets for once-daily administration
Logidhasan et al. Formulation and in vitro evaluation of bilayer floating tablets of Aceclofenac and Ranitidine Hcl
KR20260012791A (ko) 향상된 약물 경구 생체이용률을 갖는 조성물 및 이의 방법
CL2009001613A1 (es) Proceso para preparar granulos de ibuprofeno altamente dispersables y de flujo libre que comprende: poner en un granulador de alto corte una mezcla mayor que 80 p/p de dihidrato sodico de ibuprofeno, 1-4 p/p de carbonato sodico, 1-15 p/p de pvp y 8-12 p/p de agua, granular, secar y tamizar; formulacion; util como antiinflamatorio.
Ogata et al. A novel injection strategy of flurbiprofen axetil by inhibiting protein binding with 6-methoxy-2-naphthylacetic acid
WO2015016695A1 (es) Novedoso sistema farmacéutico de entrega bifásica para el tratamiento del dolor y la inflamación
WO2008037224A3 (es) Forma de dosificación de liberación controlada que contiene lercanidipina y un ácido que mejora el funcionamiento
Bhagiyalakshmi et al. Recent developments in chromatography for pharmaceutical analysis
PS et al. RP-HPLC Assay Method for simultaneous determination of Perindopril Erbumine and Indapamide combination in bulk and tablet dosage form